SecBot SecBot
8-K ·Filed Apr 23, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001096906-26-000602
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Monitor management's ability to offset the permanent loss of $2.5M in annual revenue from PendoTECH and the China distributor with new product sales and organic growth. The stock's recent 11% price increase since year-end may be overestimating the company's recovery potential.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.87
T+0 close · Apr 23, 2026 · via day close
Latest settled
+2.11%
T+60 · $69.30
Vs SPY
−2.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $67.87entry
  2. T+1 · 7mo ago −1.03%α −1.82% · $67.17
  3. T+5 · 7mo ago −4.18%α −5.66% · $65.03
  4. T+20 · 6mo ago −5.45%α −10.09% · $64.17
  5. T+60 · 4mo ago +2.11%α −2.91% · $69.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Utah Medical Products (UTMD) reported Q1 2026 earnings with revenue of $8.72M, down 10.2% YoY, and EPS of $0.818, down 11.0%. The decline was driven by the expected loss of $857K in sales from two former customers (PendoTECH and a China distributor), partially offset by a 47.4% increase in domestic Filshie device sales. Gross margin improved to 60.6% due to favorable product mix and a one-time inventory adjustment.

Key Financial Metrics

EPS
$0.82
Revenue
$8.7M
-10.2% YoY
Rating
miss
Gross Margin
60.6%

Key Facts

  • Q1 2026 revenue was $8,722K, down 10.2% from $9,710K in Q1 2025
  • EPS was $0.818, down 11.0% from $0.919 in Q1 2025
  • Gross margin improved to 60.6% from 57.0% in Q1 2025
  • Operating income declined 18.7% to $2,565K
  • Loss of $857K in sales from PendoTECH and China distributor accounted for 87% of the revenue decline
  • Domestic Filshie device sales increased 47.4% to $493K
  • Company repurchased 2,196 shares in Q1 2026 at an average price of $58.58

Financial Impact

Revenue declined $988K (-10.2%) and EPS declined $0.101 (-11.0%) compared to Q1 2025

revenueepsgross_marginoperating_income

Risk Factors

  • Permanent loss of $2.5M in annual revenue from two key customers
  • Increased litigation expenses and U.S. healthcare costs pressured operating expenses
  • Management's projection of offsetting lost revenue with new products carries substantial uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001096906-26-000602
Document: utmd-20260423_8k.htm0001096906-26-000602
Document: 0001096906-26-000602-index-headers.html0001096906-26-000602
Document: 0001096906-26-000602-index.html0001096906-26-000602
Document: 0001096906-26-000602.txt0001096906-26-000602
8-K Data (Synthetic)0001096906-26-000602

US Market Status

Market Closed · Opens in 5h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026